Cargando...
Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells
PURPOSE: Use of enzalutamide has produced a revolutionary change in the treatment of advanced prostate cancer. However, clinical resistance to enzalutamide can develop swiftly in initial responders. This study aimed to test whether overexpression of IL-6 and constitutive activation of Stat3 in prost...
Gardado en:
| Publicado en: | Prostate |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2013
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4437226/ https://ncbi.nlm.nih.gov/pubmed/24307657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22741 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|